Some of you are extremely short sighted. Go on to the Orbimed website. have a look at their news stream. A company Orbimed have in their portfolio, Cardioxyl was acquired by Bristol Myers Squibb for $300 Million upfront with $1.78 Billion in Milestone payments. Granted, Cardioxyl is not a cancer treatment, but this deal gives an example of some of the transactions Orbimed have been involved with. Take a chill pill and watch this unfold.
"Bristol-Myers Squibb will pay $300 million in cash and up to $1.78 billion in milestone payments to acquire North Carolina-based Cardioxyl Pharmaceuticals. The 10-year-old firm is developing small-molecule drugs for cardiovascular diseases based on scientific work originating at Johns Hopkins University. Cardioxyl’s lead candidate, CXL-1427, is a nitroxyl donor in Phase II clinical development for heart failure. According to BMS, the drug doesn’t just treat symptoms but potentially could change the course of the disease ."
- Forums
- ASX - By Stock
- VLA
- Orbimed
Orbimed, page-10
-
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online